Breaking AI & Tech News Analyzed

GSK has revealed promising early results for its treatment for gynaecological cancers, Mocertatug Rezetecan (Mo-Rez), as its chief executive, Luke Miels, seeks to speed up drug development at the group.The company reported that in an early-stage trial, Mo-Rez shrank or eliminated tumours in 62% of patients with ovarian cancer where chemotherapy had failed, and in 67% of those with endometrial cancer.GSK acquired the Mo-Rez cancer treatment, an antibody-drug conjugate (ADC), from China’s Hansoh Pharma in late 2023, and has trialled it in 224 patients around the world, including the UK, over the past year. Few patients needed to stop treatment because of side-effects, the most common being nausea. It is administered every three weeks via intravenous infusion.Combined with data from a separate, intermediate trial in China, these results give GSK the confidence to go straight to late-stage trials, with five clinical studies planned globally in the next few months, including on patients in the UK.Presenting the results at the Society of Gynecologic Oncology’s annual meeting on women’s cancer in Puerto Rico, Hesham Abdullah, GSK’s global head of cancer research and development, said: “Treatment of gynaecological cancers remains a major challenge, with a pressing need for new therapies that offer improved response rates. With Mo-Rez we now have compelling evidence of a promising clinical profile.”Endometrial cancer affects 1.6 million women globally, with 417,000 new cases each year. Ovarian cancer affects 843,000 people, with 240,000 new cases annually.Abdullah described Mo-Rez as a “key asset” in the company’s growing cancer portfolio, expected to be a blockbuster drug with peak annual sales of more than £2bn, which GSK hopes will help it achieve its 2031 sales target of £40bn.

Malina Lee, a 31‑year‑old wedding baker from San Antonio, joined TikTok in 2020 to pass the lockdown‑induced boredom and promote her business. Four years later, an anonymous commenter called “PickleFart” noticed an asymmetrical neck in one of her videos and suggested she check for a goiter.The tip proved accurate: doctors confirmed thyroid cancer. Lee received prompt treatment and, within a year, was declared cancer‑free. She told the outlet that her oncologist was amazed at how early the disease was caught, crediting the TikTok comment as the catalyst.Lee’s experience is part of a growing trend where TikTok’s hyper‑targeted algorithm surfaces health‑related content that resonates with users’ unnoticed symptoms. In several cases, community members have flagged potential conditions that clinicians initially missed.The “PickleFart” persona belongs to Billie Jean Tuomi, who calls herself the “thyroid avenger.” A thyroid‑cancer survivor herself (diagnosed in 2012), Tuomi now scans videos for neck asymmetry and gently advises creators to seek a thyroid panel—a blood test measuring hormone levels and antibodies. The American Thyroid Association recommends adults start routine thyroid testing at age 35, or annually for high‑risk individuals.Tuomi estimates she has flagged dozens of videos, with at least four confirmed serious thyroid issues, including Lee’s. She stresses she does not claim to diagnose, merely urges viewers to consult a physician. After a viral comment, she received a flood of private messages with neck photos, prompting her to change her username.Lee, inspired by Tuomi’s intervention, has begun commenting on other users’ videos, helping one individual discover an enlarged thyroid that required removal. She describes the process as a “domino effect” of community‑driven health awareness.Medical professionals acknowledge the double‑edged nature of this phenomenon. Craig Mittleman, director of emergency services at Lawrence + Memorial Hospital, notes a rise in patients arriving with self‑diagnoses sourced from social media. While this can empower patients to ask informed questions, it also burdens clinicians with debunking misinformation.Gender disparities amplify the issue: research shows women are more likely to seek health information online, often after feeling dismissed by traditional providers. TikTok user Tori Mosser, a 23‑year‑old filmmaker, credits a direct message suggesting chronic appendicitis for prompting surgery that resolved her chronic vomiting episodes.Both Lee and Mosser emphasize the therapeutic value of finding a supportive community on TikTok, especially for invisible or chronic illnesses that are frequently minimized in clinical settings.

Eamonn Holmes, the 66‑year‑old presenter of GB News’s breakfast programme, is recovering in hospital after suffering a stroke last week.A GB News spokesperson confirmed that the Northern Irish broadcaster is responding well to treatment and has requested privacy while focusing on his recovery. The network added that “his colleagues and everyone at GB News wish him a speedy recovery and look forward to welcoming him back when he is ready.”In Holmes’s absence, the channel said that Alex Armstrong will co‑anchor the morning slot alongside Ellie Costello for the coming week.Holmes, who previously fronted ITV’s This Morning and co‑presented with his former wife Ruth Langsford for 14 years, has a documented history of serious health issues. He has undergone spinal surgery, a double hip replacement, and endured multiple falls, including a live on‑air incident when a studio chair collapsed.Speaking about that on‑air fall, Holmes recalled, “It was a bit of a shock for me because I’d had a fall in my bathroom two weeks earlier that hospitalised me, and it hit me again right in the back.” He described the aftermath as “really, really sore.”His health struggles have also impacted his personal life. In 2022, Holmes told the Sun that chronic pain and mobility problems strained his marriage to Langsford, and he later disclosed a dislocated pelvis in 2021 that led to three slipped discs.Holmes is now in a relationship with 44‑year‑old counsellor Katie Alexander. The pair were photographed together at a recent event, with Holmes using a wheelchair.GB News chief executive Angelos Frangopoulos expressed support, stating, “Eamonn is a loved member of the GB News family, and we’re with him every step of the way as he recovers.”

The latest offering from writer Theo Jamieson and director Adam Lenson is a boldly conceived musical that thrusts a turbulent romance into a sci‑fi framework. The story follows a young astronaut, Daniel, who vanishes from his shuttle with barely enough fuel, prompting a quest to uncover the motives behind his reckless flight.Stuart Thompson (as Daniel) and Poppy Gilbert (as Emily) anchor the piece with performances that are both visceral and nuanced. Their chemistry captures the push‑pull of a relationship scarred by childhood bullying, parental betrayal, and a shared history of trauma, delivering songs that soar and hit hard.Visually, the production leans heavily on interstellar projections that transform the stage into a shifting cosmos, while the score oscillates between Sondheim‑style wit and full‑blown symphonic passages. This combination creates an epic sense of strangeness that distinguishes Flyby from more conventional West End fare.However, the narrative’s fragmented structure hampers its emotional payoff. The non‑chronological storytelling leaves critical gaps, and the metaphor of being "stranded in space" feels over‑extended—especially with the protagonist’s surname, Defoe, a thin nod to Robinson Crusoe. The three narrators, played by Simbi Akande, Gina Beck, and Rupert Young, often drift into digressive asides that dilute the central arc.Despite these flaws, moments of brilliance emerge, particularly in the musical’s treatment of mental‑health themes. The show hints at the potential to join the ranks of modern theatre successes like Next to Normal and Dear Evan Hansen, should its structural rough edges be smoothed.The production is currently staged at Southwark Playhouse, Borough, London and will run through 16 May. Audiences seeking a daring blend of emotional intensity and cosmic spectacle will find Flyby a compelling, if imperfect, experience.

Prosecutors in Florida have moved to subpoena Tiger Woods' prescription drug records from a pharmacy, following his recent vehicle crash and DUI arrest. The legendary golfer's records from Lewis Pharmacy in Palm Beach, Florida, are being sought for the period from the start of the year through last month.The subpoena aims to obtain comprehensive details on Woods' prescription medication, including:the times prescriptions were filledthe number of pills dispenseddosage amountsany instructions provided with the medication, such as warnings about drivingAccording to court documents, prosecutors in Martin County, Florida, are seeking this information to aid in their investigation. Any objections to the subpoena must be filed within 10 days. Woods has pleaded not guilty in his DUI case.Woods' vehicle crashed on a beachside road on Jupiter Island, where he was traveling at high speeds in a 30-mile per hour zone. The accident resulted in $5,000 in damage to the truck. Although a Breathalyzer test showed no signs of alcohol, Woods refused a urine test.Following the incident, Woods announced he would be stepping away to seek treatment. This is not his first leave of absence following a car crash; in 2009, he took a four-month break after a previous accident.

A 47‑year‑old woman who had endured three life‑threatening autoimmune diseases for more than a decade is now living a near‑normal life after an experimental CAR‑T cell therapy reset her immune system at University Hospital Erlangen in Germany.Before the procedure she had exhausted nine different treatments with no lasting benefit, relying on daily blood transfusions and continuous anticoagulation to manage her illnesses.Within weeks of the infusion, doctors observed rapid improvement in all three conditions—a world‑first outcome. She has remained in treatment‑free remission for 14 months and has largely returned to everyday activities.Prof Fabian Müller, who led the team, called the speed and depth of the response “remarkable” and said the therapy “significantly improved her quality of life.” He emphasized that clinical trials are required to determine how durable the effect is and whether it can help other autoimmune patients.The patient suffered from three distinct disorders: autoimmune haemolytic anaemia (AIHA), where rogue immune cells destroy red blood cells; immune thrombocytopenia (ITP), which depletes platelets and raises bleeding risk; and antiphospholipid syndrome (APS), which promotes dangerous blood clots. All three stem from malfunctioning B‑cells.With no conventional options left, doctors turned to CAR‑T therapy, a technique that has revolutionised treatment for certain cancers. They harvested her white‑blood cells, isolated the T‑cells, engineered them to recognise the CD19 protein on B‑cells, and reinfused the modified cells.The engineered T‑cells swiftly eliminated the pathogenic B‑cells. She received her last blood transfusion a week after treatment and was able to perform routine tasks within two weeks. Follow‑up tests showed a reconstituted, healthy B‑cell population, suggesting an immune reset. The findings were published in the journal Med.She still exhibits a mildly low white‑cell count and slightly elevated liver enzymes, which researchers attribute to the cumulative impact of prior therapies rather than the CAR‑T product.Rheumatology expert Prof Ben Parker of Manchester University NHS Foundation Trust described the case as encouraging, noting that “the prolonged response off normal therapy suggests there has been an immune reset.” However, he warned that case reports alone cannot confirm efficacy and highlighted ongoing trials for lupus, myositis, multiple sclerosis, systemic sclerosis, vasculitis, and other autoimmune conditions.

As rising temperatures push snakes and humans into closer contact, the world faces an estimated 5.5 million snakebites each year, resulting in 138,000 deaths and 400,000 lasting disabilities. In response, a Wisconsin‑based amateur scientist has taken an extreme route to help solve the crisis.For almost 20 years, Tim Friede, a former window cleaner, allowed some of the planet’s most lethal snakes to bite him, accumulating over 200 intentional bites. His goal: to provoke his own immune system into producing antibodies that could be harvested for a near‑universal antivenom.The endeavor has been perilous. Friede survived a coma after being bitten by two cobras within an hour, endured anaphylactic shocks, lost tissue in a finger, and even had to cut necrotic muscle from his leg. Yet he persisted, eventually becoming immune to the inland taipan—the world’s most venomous snake, whose single bite can kill more than 100 people.In 2019, California biotech firm Centivax hired Friede to extract his antibodies. Early laboratory work showed that his serum can neutralise toxins from 19 elapid species, including cobras, mambas, taipans, coral snakes and kraits—roughly half of all venomous snakes worldwide.The next step is a veterinary trial in Australia, slated for later this year, before any human application. If successful, the antivenom could dramatically reduce the burden of snakebite in low‑income regions across Asia and Africa, where most victims live.Climate scientists warn that warming climates will expand snake habitats and increase human exposure, as illustrated by the recent surge of rattlesnake bites in California’s Ventura County. This amplifies the urgency for scalable, affordable antivenoms, especially as international aid budgets face cuts and manufacturing capacity remains insufficient.Friede’s unconventional path underscores a broader lesson: confronting emerging health threats may require bold, unconventional science, but the potential payoff—a life‑saving treatment for millions—could be transformative.

The United States' newly disclosed arrangement to transfer certain detainees to third‑country destinations has triggered a wave of criticism across the Democratic Republic of Congo (DRC). Local authorities and human‑rights groups argue that the deal undermines the DRC's sovereignty and raises serious concerns about the treatment of deportees. While details of the agreement remain limited, the backlash underscores growing tensions over migration policies that involve multiple nations. Critics in the DRC are calling for greater transparency and for the United States to reassess the humanitarian implications of the deportation scheme. Stakeholders emphasize that any such arrangement must comply with international law and respect the rights of individuals facing removal, warning that failure to do so could damage diplomatic relations between the two countries.

Researchers have made a significant breakthrough in understanding why weight-loss medications, such as GLP1 receptor agonists, work better for some individuals than others. A recent study published in Nature has identified genetic variations in two genes involved in gut hormone pathways that regulate appetite and digestion. These genetic variations may help account for different weight-loss results or side-effects when taking glucagon-like peptide 1 (GLP1) medicines, which mimic natural gut hormones to regulate appetite, insulin release, and digestion. The study analyzed data from 27,885 patients on GLP1 drugs and found that specific genetic variants were associated with slightly more weight loss or side-effects like nausea and vomiting. The findings suggest that genetic differences may contribute to why people respond differently to weight-loss jabs. However, the overall impact of genetics appeared to be modest, with non-genetic factors such as sex, drug type, dose, and duration appearing to explain a substantially larger proportion of variability. The study's results reinforce that while there is substantial variability in response to GLP1 therapies, genetics is only one part of a much more complex picture. According to Marie Spreckley, an obesity expert at the University of Cambridge, the study provides plausible evidence that genetic variants could affect outcomes. However, she notes that the magnitude of these genetic effects is small in clinical terms, and that behavioral, clinical, and treatment-related factors remain the dominant drivers of outcomes. The study's authors suggest that their findings could support future efforts to use genetic information when making treatment choices for obesity. However, Spreckley cautions that the evidence is not yet sufficient to support using genetic information to guide treatment decisions in routine clinical practice.